Irbesartan, an angiotensin II type 1 receptor blocker, inhibits colitis-associated tumourigenesis by blocking the MCP-1/CCR2 pathway.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
07 10 2021
07 10 2021
Historique:
received:
12
07
2021
accepted:
20
09
2021
entrez:
8
10
2021
pubmed:
9
10
2021
medline:
13
1
2022
Statut:
epublish
Résumé
The introduction of anti-inflammatory therapies has enabled substantial improvement of disease activity in patients with inflammatory bowel diseases (IBD). However, IBD can lead to serious complications such as intestinal fibrosis and colorectal cancer. Therefore, novel therapies reducing the development of these complications are needed. Angiotensin II (Ang II) promotes tissue inflammation by stimulating the production of monocyte chemoattractant protein-1 (MCP-1) or proinflammatory cytokines. It plays a pivotal role in IBD progression. Although blockade of Ang II has been reported to ameliorate experimental colitis and reduce colorectal cancer risk, the cellular and molecular mechanisms remain poorly understood. Our previous work showed that irbesartan, an Ang II type 1 receptor blocker, reduced the number of C-C chemokine receptor 2-positive (CCR2
Identifiants
pubmed: 34620946
doi: 10.1038/s41598-021-99412-8
pii: 10.1038/s41598-021-99412-8
pmc: PMC8497524
doi:
Substances chimiques
Angiotensin II Type 1 Receptor Blockers
0
Chemokine CCL2
0
Receptors, CCR2
0
Dextran Sulfate
9042-14-2
Irbesartan
J0E2756Z7N
Azoxymethane
MO0N1J0SEN
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
19943Informations de copyright
© 2021. The Author(s).
Références
Li, C. & Kuemmerle, J. F. Mechanisms that mediate the development of fibrosis in patients with Crohn’s disease. Inflamm. Bowel Dis. 20, 1250–1258 (2014).
pubmed: 24831560
doi: 10.1097/MIB.0000000000000043
Beaugerie, L. & Itzkowitz, S. H. Cancers complicating inflammatory bowel disease. N. Engl. J. Med. 372, 1441–1452 (2015).
pubmed: 25853748
doi: 10.1056/NEJMra1403718
Kinugasa, T. & Akagi, Y. Status of colitis-associated cancer in ulcerative colitis. World J. Gastrointest. Oncol. 8, 351–357 (2016).
pubmed: 27096030
pmcid: 4824713
doi: 10.4251/wjgo.v8.i4.351
Zigmond, E. et al. Ly6Chi monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigen-presenting cells. Immunity 37, 1076–1090 (2012).
pubmed: 23219392
doi: 10.1016/j.immuni.2012.08.026
Nakatsumi, H., Matsumoto, M. & Nakayama, K. I. Noncanonical pathway for regulation of CCL2 expression by an mTORC1-FOXK1 axis promotes recruitment of tumor-associated macrophages. Cell Rep. 21, 2471–2486 (2017).
pubmed: 29186685
doi: 10.1016/j.celrep.2017.11.014
Kohno, T. et al. Angiotensin-receptor blockade reduces border zone myocardial monocyte chemoattractant protein-1 expression and macrophage infiltration in post-infarction ventricular remodeling. Circ. J. 72, 1685–1692 (2008).
pubmed: 18753699
doi: 10.1253/circj.CJ-08-0115
Yao, W. et al. A natural CCR2 antagonist relieves tumor-associated macrophage-mediated immunosuppression to produce a therapeutic effect for liver cancer. EBioMedicine 22, 58–67 (2017).
pubmed: 28754304
pmcid: 5552238
doi: 10.1016/j.ebiom.2017.07.014
Moore, B. B. et al. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am. J. Pathol. 166, 675–684 (2005).
pubmed: 15743780
pmcid: 1780139
doi: 10.1016/S0002-9440(10)62289-4
Kitamura, T. et al. CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. J. Exp. Med. 212, 1043–1059 (2015).
pubmed: 26056232
pmcid: 4493415
doi: 10.1084/jem.20141836
Bucala, R., Spiegel, L. A., Chesney, J., Hogan, M. & Cerami, A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol. Med. 1, 71–81 (1994).
pubmed: 8790603
pmcid: 2229929
doi: 10.1007/BF03403533
Terai, S. et al. Bone marrow derived “fibrocytes” contribute to tumor proliferation and fibrosis in gastric cancer. Gastric Cancer 18, 306–313 (2015).
pubmed: 24792410
doi: 10.1007/s10120-014-0380-0
Kuroda, N. et al. Infiltrating CCR2+ monocytes and their progenies, fibrocytes, contribute to colon fibrosis by inhibiting collagen degradation through the production of TIMP-1. Sci. Rep. 9, 8568 (2019).
pubmed: 31189971
pmcid: 6562037
doi: 10.1038/s41598-019-45012-6
Popivanova, B. K. et al. Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice. Cancer Res. 69, 7884–7892 (2009).
pubmed: 19773434
doi: 10.1158/0008-5472.CAN-09-1451
Regan, D. P. et al. The angiotensin receptor blocker losartan suppresses growth of pulmonary metastases via AT1R-independent inhibition of CCR2 signaling and monocyte recruitment. J. Immunol. 202, 3087–3102 (2019).
pubmed: 30971441
doi: 10.4049/jimmunol.1800619
An, J. et al. Targeting CCR2 with its antagonist suppresses viability, motility and invasion by downregulating MMP-9 expression in non-small cell lung cancer cells. Oncotarget 8, 39230–39240 (2017).
pubmed: 28424406
pmcid: 5503609
doi: 10.18632/oncotarget.16837
Jaszewski, R. et al. Increased colonic mucosal angiotensin I and II concentrations in Crohn’s colitis. Gastroenterology 98, 1543–1548 (1990).
pubmed: 2159930
doi: 10.1016/0016-5085(90)91088-N
Daugherty, A., Manning, M. W. & Cassis, L. A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J. Clin. Invest. 105, 1605–1612 (2000).
pubmed: 10841519
pmcid: 300846
doi: 10.1172/JCI7818
Suzuki, Y. et al. Inflammation and angiotensin II. Int. J. Biochem. Cell Biol. 35, 881–900 (2003).
pubmed: 12676174
doi: 10.1016/S1357-2725(02)00271-6
Benigni, A., Cassis, P. & Remuzzi, G. Angiotensin II revisited: New roles in inflammation, immunology and aging. EMBO Mol. Med. 2, 247–257 (2010).
pubmed: 20597104
pmcid: 3377325
doi: 10.1002/emmm.201000080
Shi, Y. et al. Activation of the renin-angiotensin system promotes colitis development. Sci. Rep. 6, 27552 (2016).
pubmed: 27271344
pmcid: 4897651
doi: 10.1038/srep27552
Chen, X. L., Tummala, P. E., Olbrych, M. T., Alexander, R. W. & Medford, R. M. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ. Res. 83, 952–959 (1998).
pubmed: 9797345
doi: 10.1161/01.RES.83.9.952
Nakamura, A., Johns, E. J., Imaizumi, A., Yanagawa, Y. & Kohsaka, T. Effect of β2-adrenoceptor activation and angiotensin II on tumor necrosis factor and interleukin 6 gene transcription in the rat renal resident macrophage cells. Cytokine 11, 759–765 (1999).
pubmed: 10525314
doi: 10.1006/cyto.1999.0488
Chehl, N. et al. Angiotensin II regulates the expression of monocyte chemoattractant protein-1 in pancreatic cancer cells. J. Gastrointest. Surg. 13, 2189–2200 (2009).
pubmed: 19816747
doi: 10.1007/s11605-009-1055-8
Yoshiji, H. et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 34, 745–750 (2001).
pubmed: 11584371
doi: 10.1053/jhep.2001.28231
Ishibashi, M. et al. Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circ. Res. 94, 1203–1210 (2004).
pubmed: 15059935
doi: 10.1161/01.RES.0000126924.23467.A3
Urushihara, M. et al. Addition of angiotensin II type 1 receptor blocker to CCR2 antagonist markedly attenuates crescentic glomerulonephritis. Hypertension 57, 586–593 (2011).
pubmed: 21282555
doi: 10.1161/HYPERTENSIONAHA.110.165704
Miguel-Carrasco, J. L. et al. Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites. Sci. Rep. 7, 41865 (2017).
pubmed: 28157237
pmcid: 5291109
doi: 10.1038/srep41865
Ino, K. et al. Monocytes infiltrate the pancreas via the MCP-1/CCR2 pathway and differentiate into stellate cells. PLoS ONE 9, e84889 (2014).
pubmed: 24416305
pmcid: 3885670
doi: 10.1371/journal.pone.0084889
Tanaka, T. et al. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci. 94, 965–973 (2003).
pubmed: 14611673
doi: 10.1111/j.1349-7006.2003.tb01386.x
Soncin, I. et al. The tumour microenvironment creates a niche for the self-renewal of tumour-promoting macrophages in colon adenoma. Nat. Commun. 9, 582 (2018).
pubmed: 29422500
pmcid: 5805689
doi: 10.1038/s41467-018-02834-8
Xu, J. et al. CCR2 mediates the uptake of bone marrow-derived fibroblast precursors in angiotensin II-induced cardiac fibrosis. Am. J. Physiol. Heart Cir. Physiol. 301, H538–H547 (2011).
doi: 10.1152/ajpheart.01114.2010
Scholten, D. et al. Migration of fibrocytes in fibrogenic liver injury. Am. J. Pathol. 179, 189–198 (2011).
pubmed: 21703401
pmcid: 3123781
doi: 10.1016/j.ajpath.2011.03.049
Reich, B. et al. Fibrocytes develop outside the kidney but contribute to renal fibrosis in a mouse model. Kidney Int. 84, 78–89 (2013).
pubmed: 23486523
doi: 10.1038/ki.2013.84
Wang, X., Zhao, W., Ransohoff, R. M. & Zhou, L. Identification and function of fibrocytes in skeletal muscle injury repair and muscular dystrophy. J. Immunol. 197, 4750–4761 (2016).
pubmed: 27913649
doi: 10.4049/jimmunol.1601308
Grimm, M. C., Elsbury, S. K. O., Pavli, P. & Doe, W. F. Enhanced expression and production of monocyte chemoattractant protein-1 in inflammatory bowel disease mucosa. J. Leukoc. Biol. 59, 804–812 (1996).
pubmed: 8691064
doi: 10.1002/jlb.59.6.804
Deshmane, S. L., Kremlev, S., Amini, S. & Sawaya, B. E. Monocyte chemoattractant protein-1 (MCP-1): An overview. J. Interferon Cytokine Res. 29, 313–326 (2009).
pubmed: 19441883
pmcid: 2755091
doi: 10.1089/jir.2008.0027
Sakai, N. et al. MCP-1/CCR2-dependent loop for fibrogenesis in human peripheral CD14-positive monocytes. J. Leukoc. Biol. 79, 555–563 (2006).
pubmed: 16415174
doi: 10.1189/jlb.0305127
Marshall, T. G., Lee, R. E. & Marshall, F. E. Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b. Theor. Biol. Med. Model 3, 1 (2006).
pubmed: 16403216
pmcid: 1360063
doi: 10.1186/1742-4682-3-1
Fujino, M. et al. A small difference in the molecular structure of angiotensin II receptor blockers induces AT
pubmed: 20668453
pmcid: 3891520
doi: 10.1038/hr.2010.135
Tsukuda, K. et al. Irbesartan attenuates ischemic brain damage by inhibition of MCP-1/CCR2 signaling pathway beyond AT
pubmed: 21575596
doi: 10.1016/j.bbrc.2011.04.142
Santiago, O. I., Rivera, E., Ferder, L. & Appleyard, C. B. An angiotensin II receptor antagonist reduces inflammatory parameters in two models of colitis. Reg. Peptides 146, 250–259 (2008).
doi: 10.1016/j.regpep.2007.10.004
Zhang, X. et al. Suppression colitis and colitis-associated colon cancer by anti-S100a9 antibody in mice. Front. Immunol. 8, 1774 (2017).
pubmed: 29326691
pmcid: 5733461
doi: 10.3389/fimmu.2017.01774
Kanehara, K. et al. The indole compound MA-35 attenuates tumorigenesis in an inflammation-induced colon cancer model. Sci. Rep. 9, 12739 (2019).
pubmed: 31484999
pmcid: 6726640
doi: 10.1038/s41598-019-48974-9
Suzuki, N. et al. Alpha-blockers as colorectal cancer chemopreventive: Findings from a case-control study, human cell cultures, and in vivo preclinical testing. Cancer Prev. Res. 12, 185–194 (2019).
doi: 10.1158/1940-6207.CAPR-18-0288
Paul, M., Poyan Mehr, A. & Kreutz, R. Physiology of local renin-angiotensin systems. Physiol. Rev. 86, 747–803 (2006).
pubmed: 16816138
doi: 10.1152/physrev.00036.2005
Leung, P. S. The physiology of a local renin-angiotensin system in the pancreas. J. Physiol. 580, 31–37 (2007).
pubmed: 17218353
pmcid: 2075423
doi: 10.1113/jphysiol.2006.126193
Yvan-Charvet, L. & Quignard-Boulangé, A. Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity. Kidney Int. 79, 162–168 (2011).
pubmed: 20944545
doi: 10.1038/ki.2010.391
Garg, M. et al. Review article: The pathophysiological roles of the renin-angiotensin system in the gastrointestinal tract. Aliment. Pharmacol. Ther. 35, 414–428 (2012).
pubmed: 22221317
pmcid: 7159631
doi: 10.1111/j.1365-2036.2011.04971.x
Abdul-Hafez, A., Mohamed, T., Omar, H., Shemis, M. & Uhal, B. D. The renin angiotensin system in liver and lung: Impact and therapeutic potential in organ fibrosis. J. Lung Pulm. Respir. Res. 5, 00160 (2018).
pubmed: 30175235
pmcid: 6114139
He, L. et al. Renin-angiotensin system promotes colonic inflammation by inducing T
pubmed: 30995068
pmcid: 6620584
doi: 10.1152/ajpgi.00053.2019
Spencer, A. U. et al. Reduced severity of a mouse colitis model with angiotensin converting enzyme inhibition. Dig. Dis. Sci. 52, 1060–1070 (2007).
pubmed: 17342403
pmcid: 1866259
doi: 10.1007/s10620-006-9124-2
Childers, W. K. Interactions of the renin-angiotensin system in colorectal cancer and metastasis. Int. J. Colorectal. Dis. 30, 749–752 (2015).
pubmed: 25592047
doi: 10.1007/s00384-014-2118-1
Chen, X., Yi, C. H. & Ya, K. G. Renin-angiotensin system inhibitor use and colorectal cancer risk and mortality: A dose–response meta analysis. J. Renin Angiotensin Aldosterone Syst. 21, 1470320319895646 (2020).
pubmed: 32627649
pmcid: 7338647
doi: 10.1177/1470320319895646
Vinay, D. S. et al. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin. Cancer Biol. 35, S185–S198 (2015).
pubmed: 25818339
doi: 10.1016/j.semcancer.2015.03.004
Miura, R. et al. Aldosterone synthesis and cytokine production in human peripheral blood mononuclear cells. J. Pharmacol. Sci. 102, 288–295 (2006).
pubmed: 17072102
doi: 10.1254/jphs.FP0060801
Tsuchiya, K. et al. Angiotensin II induces monocyte chemoattractant protein-1 expression via a nuclear factor-κB-dependent pathway in rat preadipocytes. Am. J. Physiol. Endocrinol. Metab. 291, E771–E778 (2006).
pubmed: 16705055
doi: 10.1152/ajpendo.00560.2005
Wang, C. et al. Angiotensin II induces monocyte chemoattractant protein-1 expression by increasing reactive oxygen species-mediated activation of the nuclear factor-κB signaling pathway in osteoblasts. Mol. Med. Rep. 17, 1166–1172 (2018).
pubmed: 29115506
Popivanova, B. K. et al. Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Invest. 118, 560–570 (2008).
pubmed: 18219394
pmcid: 2213370
Reilkoff, R. A., Bucala, R. & Herzog, E. L. Fibrocytes: Emerging effector cells in chronic inflammation. Nat. Rev. Immunol. 11, 427–435 (2011).
pubmed: 21597472
pmcid: 3599774
doi: 10.1038/nri2990
Abangan, R. S., Williams, C. R., Mehrotra, M., Duncan, J. D. & LaRue, A. C. MCP1 directs trafficking of hematopoietic stem cell-derived fibroblast precursors in solid tumor. Am. J. Pathol. 176, 1914–1926 (2010).
pubmed: 20167869
pmcid: 2843480
doi: 10.2353/ajpath.2010.080839
Roife, D., Fleming, J. B. & Gomer, R. H. Fibrocytes in the tumor microenvironment. Adv. Exp. Med. Biol. 1224, 79–85 (2020).
pubmed: 32036606
pmcid: 7212529
doi: 10.1007/978-3-030-35723-8_6
Garcia-de-Alba, C. et al. Expression of matrix metalloproteases by fibrocytes: Possible role in migration and homing. Am. J. Respir. Crit. Care Med. 182, 1144–1152 (2010).
pubmed: 20622038
doi: 10.1164/rccm.201001-0028OC
Yang, B. et al. Matrix metalloproteinase-9 overexpression is closely related to poor prognosis in patients with colon cancer. World J. Surg. Oncol. 12, 24 (2014).
pubmed: 24476461
pmcid: 3906768
doi: 10.1186/1477-7819-12-24
Zhang, H. et al. Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. Blood 122, 1105–1113 (2013).
pubmed: 23757729
pmcid: 3744987
doi: 10.1182/blood-2012-08-449413
Okabe, M., Ikawa, M., Kominami, K., Nakanishi, T. & Nishimune, Y. 'Green mice' as a source of ubiquitous green cells. FEBS Lett. 407, 313–319 (1997).
pubmed: 9175875
doi: 10.1016/S0014-5793(97)00313-X
Ito, R. et al. Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin. Exp. Immunol. 146, 330–338 (2006).
pubmed: 17034586
pmcid: 1942055
doi: 10.1111/j.1365-2249.2006.03214.x